Merck & Co Inc MRK
News
How Merck Scientists Are Driving Next-Generation Cancer Research
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
Summit Therapeutics Shares Triple After Drug Candidate Data
Trending: Merck to Buy Biotech Company EyeBio for $1.3 Billion
Merck could pay up to $3 billion to boost its retinal disease candidate pipeline
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Merck to Acquire EyeBio for $1.3 Billion
Merck to Acquire EyeBio
Merck Announces Third-Quarter 2024 Dividend
Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent